Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin
Vani P Sanon,1 Shalin Patel,1 Saurabh Sanon,2 Ruben Rodriguez,1 Son V Pham,1 Robert Chilton1 1Division of Cardiology, University of Texas Health Science Center at San Antonio, Audie L Murphy VA Hospital, San Antonio, TX, 2Interventional Cardiology-Structural Heart Disease, Cardiology Consultants at...
Main Authors: | Sanon VP, Patel S, Sanon S, Rodriguez R, Pham SV, Chilton R |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-05-01
|
Series: | Therapeutics and Clinical Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/differential-cardiovascular-profiles-of-sodium-glucose-cotransporter-2-peer-reviewed-article-TCRM |
Similar Items
-
Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure
by: Ting-Wei Kao, et al.
Published: (2022-12-01) -
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
by: Munteanu Madalina Andreea, et al.
Published: (2023-04-01) -
Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Increases Antioxidative Capacity and Improves Renal Function in Diabetic Rats
by: Habib Yaribeygi, et al.
Published: (2023-06-01) -
Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes
by: Sjoukje van der Hoek, et al.
Published: (2023-04-01) -
Effects of the sodium‐glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
by: Julie Kolwelter, et al.
Published: (2021-12-01)